Immutep Faces Fraud Probe After 90% Stock Collapse

Edgen Stock·Mar 17 2026, 16:29

Share to

Share to

Copy link

Key Takeaways

Biotechnology firm Immutep Limited is under investigation by law firm Levi & Korsinsky for potential securities fraud. The probe was triggered after the company's stock plummeted following the abrupt termination of its lead oncology drug trial, just weeks after management provided a positive update to investors.

Immutep is being investigated for potential federal securities law violations concerning its clinical trial disclosures.
The company's stock crashed as much as 90% after it announced on March 13, 2026, that its lead TACTI-004 trial was being halted for futility.
The investigation questions an optimistic SEC filing from January 30, 2026, which cited "strong operational progress" only six weeks before the trial's failure was revealed.

Immutep Investigated After 90% Plunge Wipes Out Shareholders

Immutep Limited is facing a formal investigation from the law firm Levi & Korsinsky concerning potential violations of federal securities laws. The probe centers on allegedly misleading statements made by the company regarding its TACTI-004 clinical trial, which culminated in a catastrophic failure and erased the majority of the company's market value.

The investigation highlights a critical discrepancy in the company's disclosures. On January 30, 2026, Immutep filed a 6-K with the SEC assuring investors of "strong operational progress" and stating that a key futility analysis was "on track." However, just six weeks later on March 13, 2026, an independent committee recommended stopping the study entirely, concluding the drug was unlikely to prove effective. The market's reaction was severe, with Immutep's stock (NASDAQ: IMMP) collapsing by as much as 90% in a single trading session.

Lead Oncology Trial Failure Dismantles Investor Confidence

The abrupt termination of the TACTI-004 study represents a significant strategic blow to Immutep, as the drug was its lead asset in the oncology space. The failure not only shutters a key development pipeline but also raises serious questions about the transparency and accuracy of the company's prior communications with investors. The January filing made no mention of negative data trends or enrollment issues that could have signaled the impending negative outcome.

This legal scrutiny now exposes Immutep to the risk of a class-action lawsuit, which could result in substantial legal costs and further damage its reputation. For investors, the gap between the company's optimistic guidance and the trial's disastrous result serves as the foundation for the potential fraud claims being explored by shareholder advocates.